In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking

doi:10.1007/s13659-017-0126-x

Natural Products and Bioprospecting ›› 2017, Vol. 7 ›› Issue (3): 249-256.DOI: 10.1007/s13659-017-0126-x

Previous Articles Next Articles

In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking

Yinglan Pu, Hui Liu, Yeheng Zhou, Jiale Peng, Yaping Li, Penghua Li, Yingying Li, Xingyong Liu, Li Zhang

School of Chemical Engineering, Sichuan University of Science & Engineering, Zigong, China

Received:2017-03-14 Revised:2017-04-05 Online:2018-02-06 Published:2017-06-24
Supported by:
We gratefully thank financial assistance from the Science and Technology Innovation Talent Project of Sichuan province (Grant number 2016073).

In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking

Yinglan Pu, Hui Liu, Yeheng Zhou, Jiale Peng, Yaping Li, Penghua Li, Yingying Li, Xingyong Liu, Li Zhang

School of Chemical Engineering, Sichuan University of Science & Engineering, Zigong, China

通讯作者: Li Zhang,e-mail:zhangli19700554@163.com
基金资助:
We gratefully thank financial assistance from the Science and Technology Innovation Talent Project of Sichuan province (Grant number 2016073).

Abstract

Abstract: Coagulation Factor Xa (FXa) is the crucial enzyme at the convergent point of the intrinsic and extrinsic coagulation pathways. The inhibition of FXa is an effective approach against thrombotic diseases. In the present study, a specific strategy is reported to discover 10 novel FXa inhibitors based on ligand-based (pharmacophore) virtual screening and molecular docking analysis from a dataset of specs(containing 220000 molecules). The binding modes analysis provide insights into the contribution of particular structural moieties of the compounds towards their activity against FXa, and 10 novel structural compounds were discovered as potent candidate molecules. This work could be helpful in further design and development of FXa inhibitors.

Key words: FXa, Thrombotic diseases, Pharmacophore, Docking

摘要： Coagulation Factor Xa (FXa) is the crucial enzyme at the convergent point of the intrinsic and extrinsic coagulation pathways. The inhibition of FXa is an effective approach against thrombotic diseases. In the present study, a specific strategy is reported to discover 10 novel FXa inhibitors based on ligand-based (pharmacophore) virtual screening and molecular docking analysis from a dataset of specs(containing 220000 molecules). The binding modes analysis provide insights into the contribution of particular structural moieties of the compounds towards their activity against FXa, and 10 novel structural compounds were discovered as potent candidate molecules. This work could be helpful in further design and development of FXa inhibitors.

关键词: FXa, Thrombotic diseases, Pharmacophore, Docking

Yinglan Pu, Hui Liu, Yeheng Zhou, Jiale Peng, Yaping Li, Penghua Li, Yingying Li, Xingyong Liu, Li Zhang. In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking[J]. Natural Products and Bioprospecting, 2017, 7(3): 249-256.

References

1. R.G. Macfarlane, Nature 202, 498-499 (1964)
2. R.L. Adams, R.J. Bird, Nephrology 14, 462-470 (2009)
3. C.B. Granger, J.H. Alexander, J.J.V. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, H.R. Al-Khalidi, J. Ansell, D. Atar, A. Avezum, M.C. Bahit, R. Diaz, J.D. Easton, J.A. Ezekowitz, G. Flaker, D. Garcia, M. Geraldes, B.J. Gersh, S. Golitsyn, S. Goto, A.G. Hermosillo, S.H. Hohnloser, J. Horowitz, P. Mohan, P. Jansky, B.S. Lewis, J.L. Lopez-Sendon, P. Pais, A. Parkhomenko, F.W.A. Verheugt, J. Zhu, L. Wallentin, N. Engl. J. Med. 365, 981-992 (2011)
4. T.J. Milling Jr., S. Kaatz, Am. J. Emerg. Med. 34, 39-45 (2016)
5. K.L. Furie, S.E. Kasner, R.J. Adams, G.W. Albers, R.L. Bush, S.C. Fagan, J.L. Halperin, S.C. Johnston, I. Katzan, W.N. Kernan, P.H. Mitchell, B. Ovbiagele, Y.Y. Palesch, R.L. Sacco, L.H. Schwamm, S. Wassertheil-Smoller, T.N. Turan, D. Wentworth, The American Heart Association/American Stroke Association, Stroke 42, 227-276 (2011)
6. M. Writing Group, V.L. Roger, A.S. Go, D.M. Lloyd-Jones, E.J. Benjamin, J.D. Berry, W.B. Borden, D.M. Bravata, S. Dai, E.S. Ford, C.S. Fox, H.J. Fullerton, C. Gillespie, S.M. Hailpern, J.A. Heit, V.J. Howard, B.M. Kissela, S.J. Kittner, D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, D.M. Makuc, G.M. Marcus, A. Marelli, D.B. Matchar, C.S. Moy, D. Mozaffarian, M.E. Mussolino, G. Nichol, N.P. Paynter, E.Z. Soliman, P.D. Sorlie, N. Sotoodehnia, T.N. Turan, S.S. Virani, N.D. Wong, D. Woo, M.B. Turner, Circulation 125, e2-e220 (2012)
7. T.E.P. Investigators, N. Engl. J. Med. 366, 1287-1297 (2012)
8. T.H.V. Investigators, N. Engl. J. Med. 369, 1406-1415 (2013)
9. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, U. Masiukiewicz, R. Pak, J. Thompson, G.E. Raskob, J.I. Weitz, N. Engl. J. Med. 369, 799-808 (2013)
10. T. Xue, S. Ding, B. Guo, Y. Zhou, P. Sun, H. Wang, W. Chu, G. Gong, Y. Wang, X. Chen, Y. Yang, J. Med. Chem. 57, 7770-7791 (2014)
11. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, A.L. Waldo, M.D. Ezekowitz, J.I. Weitz, J. Spinar, W. Ruzyllo, M. Ruda, Y. Koretsune, J. Betcher, M. Shi, L.T. Grip, S.P. Patel, I. Patel, J.J. Hanyok, M. Mercuri, E.M. Antman, N. Engl. J. Med. 369, 2093-2104 (2013)
12. T.E. Investigators, N. Engl. J. Med. 363, 2499-2510 (2010)
13. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, G. Breithardt, J.L. Halperin, G.J. Hankey, J.P. Piccini, R.C. Becker, C.C. Nessel, J.F. Paolini, S.D. Berkowitz, K.A.A. Fox, R.M. Califf, T. R. A. S. Committee, N. Engl. J. Med. 365, 883-891 (2011)
14. N.M. Cerqueira, D. Gesto, E.F. Oliveira, D. Santos-Martins, N.F. Bras, S.F. Sousa, P.A. Fernandes, M.J. Ramos, Arch. Biochem. Biophys. 582, 56-67 (2015)
15. M.L. Verdonk, J.C. Cole, M.J. Hartshorn, C.W. Murray, R.D. Taylor, Proteins 52, 609-623 (2003)
16. Factor Xa Specific Inhibitor that Induces the Novel Binding Model in Complex with Human Fxa. (http://www.rcsb.org/pdb/explore/explore.do?structureId=1IQI)

[1]	Orawan Jongsomjainuk, Jutatip Boonsombat, Sanit Thongnest, Hunsa Prawat, Paratchata Batsomboon, Sitthivut Charoensutthivarakul, Saroj Ruchisansakun, Kittipong Chainok, Jitnapa Sirirak, Chulabhorn Mahidol, Somsak Ruchirawat. Kaemtakols A–D, highly oxidized pimarane diterpenoids with potent anti-inflammatory activity from Kaempferia takensis [J]. Natural Products and Bioprospecting, 2023, 13(6): 55-55.
[2]	Mohammed A. Dahab, Mostafa M. Hegazy, Hatem S. Abbass. Hordatines as a Potential Inhibitor of COVID-19 Main Protease and RNA Polymerase: An In-Silico Approach [J]. Natural Products and Bioprospecting, 2020, 10(6): 453-462.
[3]	Rohan R. Narkhede, Ashwini V. Pise, Rameshwar S. Cheke, Sachin D. Shinde. Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences [J]. Natural Products and Bioprospecting, 2020, 10(5): 297-306.
[4]	Jean J. K. Bankeu, Hira Sattar, Yannick S. F. Fongang, Syeda W. Muhammadi, Conrad V. Simoben, Fidele Ntie-Kang, Guy R. T. Feuya, Marthe A. T. Tchuenmogne, Mehreen Lateef, Bruno N. Lenta, Muhammad S. Ali, Augustin S. Ngouela. Synthesis, Urease Inhibition and Molecular Modelling Studies of Novel Derivatives of the Naturally Occurring β-Amyrenone [J]. Natural Products and Bioprospecting, 2019, 9(1): 49-60.
[5]	Mehtab Parveen, Faheem Ahmad, Ali Mohammed Malla, Shaista Azaz, Mahboob Alam, Omer A. Basudan, Manuela Ramos Silva, Pedro S. Pereira Silva. Acetylcholinesterase and Cytotoxic Activity of Chemical Constituents of Clutia lanceolata Leaves and its Molecular Docking Study [J]. Natural Products and Bioprospecting, 2016, 6(6): 267-278.
[6]	Christian Bäcker, Malgorzata N. Drwal, Robert Preissner, Ulrike Lindequist. Inhibition of DNA-Topoisomerase I by Acylated Triterpene Saponins from Pittosporum angustifolium Lodd [J]. Natural Products and Bioprospecting, 2016, 6(2): 141-147.
[7]	A.Anita Margret,T.Nargis Begum, S.Parthasarathy,S.Suvaithenamudhan. A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and Depression [J]. Natural Products and Bioprospecting, 2015, 5(6): 293-306.
[8]	David Mary Rajathei, Jayakumar Preethi, Hemant K. Singh, Koilmani Emmanuvel Rajan. Molecular Docking of Bacosides with Tryptophan Hydroxylase: A Model to Understand the Bacosides Mechanism [J]. Natural Products and Bioprospecting, 2014, 4(4): 251-255.

In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking

In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 8

Recommended Articles

Metrics

Comments